Exact claim · Version 1 · Reviewed 2026-07-23
“Liraglutide has established human outcome evidence.”
A verdict on this wording and scope, not a universal grade for Liraglutide.
01 · Verdict
Supported with scope
Yes, for defined products, populations, indications, comparators, endpoints, and durations studied in major trials and reviewed labels.
- Evidence basis
- Randomized human outcomes
- Scope
- Approved liraglutide products used in the populations and indications studied.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01Liraglutide and cardiovascular outcomes in type 2 diabetesPubMed · New England Journal of Medicine · Randomized trial · 2016
Supports the scoped claim02SAXENDA (liraglutide) prescribing informationU.S. Food and Drug Administration · Drug label · 2026
Supports the scoped claim
Supports the scoped claim02SAXENDA (liraglutide) prescribing informationU.S. Food and Drug Administration · Drug label · 2026
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.